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Abstract
Malaria is an enormous global burden, causing severe morbidity and mortality. Pregnant women are amongst the most vulnerable to the development 
of severe malaria caused by the multidrug-resistant protozoan parasite Plasmodium falciparum. Artemisinin derivatives are now widely used and highly 
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Clinical trials involving animal subjects have raised concerns over the safety of artemisinin administration in early gestation. At present artemisinins are only 
recommended by the World Health Organization as safe for the treatment of malaria during the second and third trimesters. However, it is concluded that the 
risk of developing artemisinin-induced toxicity is non-inferior to comparative antimalarials, and is far outweighed by the deleterious consequences of failing 
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Introduction
Malaria is one of the most prevalent and dangerous of all tropical diseases. 
It was estimated that in 2012, 207 million people were infected with malaria, 
resulting in an estimated 627 000 deaths.1 The global burden of malaria is 
carried largely by the developing world, with economic and environmental 
instability rendering sub-Saharan Africa one of the most susceptible of 
all developing regions.1 Pregnant women are among the most vulnerable 
to developing severe malaria and if left untreated, the infection can lead to 
severe morbidity and mortality of both the mother and the unborn child.2
The World Health Organization (WHO) aims to reduce the overall incidence 
of malaria through the use of intermittent preventive treatment (IPT), 
insecticide-treated nets (ITN), and rapid clearing of parasitaemia.1,3,4
The continued emergence of multidrug-resistant strains of Plasmodium 
falciparum, the parasite responsible for most severe malaria, has threatened 
the ability of health care workers to adequately treat this disease.1,5,6 So 
far the most highly-effective anti-malarial is artemisinin; however, there is 
limited knowledge about the maternal and foetal implications resulting from 
artemisinin exposure during pregnancy.
This review seeks to identify and evaluate the current literature on maternal 
and foetal response to artemisinin treatment, in order to extrapolate the risk-
>AJAłPN=PEKKB=NPAIEOEJEJQOAEJLNACJ=J?U
Background
Malaria is a protozoan parasitic infection transmitted by the female anopheline 
mosquito.7 Five malaria parasite species, namely P. vivax, P. malariae, 
P. ovalePDAIKOPNA?AJPHUE@AJPEłA@P. knowlesi, and the most widely lethal, 
P. falciparum, have the ability to cause malaria in humans. P. falciparum is 
responsible for almost all cases of fatal malaria seen globally and is one of 
PDAIKOP@EBł?QHP PK PNA=P1,4 The initial presentation of malaria is generally 
indistinguishable from many other tropical diseases, and includes abdominal 
symptoms, fevers and chills, malaise and myalgia, nausea, vomiting and 
anorexia. In most instances once appropriate treatment has commenced the 
disease is self-limiting, with no further evidence of organ dysfunction.7
Pregnant women living in malaria-endemic regions experience fewer 
clinical symptoms when infected with the parasite. This is thought to be 
due to increased maternal immunity.8 Pregnant women affected by sporadic 
outbreaks, experience a greater incidence of clinical symptomatology. 
Epidemically-exposed women have higher parasitaemias in peripheral, 
cord and placental blood, resulting in greater risk of sequence into severe 
malaria.9-11 Regardless of the type of exposure, epidemic or endemic, 
pregnant women are physiologically more susceptible to adverse health 
complications.2,5
If malaria during pregnancy is left untreated, rapid deterioration from 
uncomplicated to complicated malaria may ensue within hours, exposing 
the mother and foetus to severe risk.4 Infected mothers may experience a 
number of sequelae including cerebral malaria, metabolic acidosis, severe 
anaemia, acute pulmonary oedema, renal failure and hypoglycaemia, likely 
ending in death.12 Foetal risks range from foetal hypoxia, intrauterine growth 
retardation including congenital and skeletal malformation, spontaneous 
abortion and pre-term pregnancies.9,10,13 Malaria further increases the risk of 
low birth weight deliveries, which is a well-known precipitating factor for poor 
physical and cognitive development and increased disease susceptibility. It 
EO=HOK=OECJEł?=JP?KJPNE>QPEJCB=?PKNPKDECDEJB=JPIKNP=HEPUN=PAOEJPDA
developing world.1,9,10,12 
Diagnosis
)=>KN=PKNU ?KJłNI=PEKJ KBI=H=NE= EJ ?KJFQJ?PEKJ SEPD OQCCAOPERA OECJO
=J@OUILPKIOEOPDALKOEPERAE@AJPEł?=PEKJKBL=N=OEPAO@QNEJCIE?NKO?KLU
analysis.9 Placental histological examination postpartum has proven to 
be the most clinically accurate in determining levels of parasite burden.14 
High placental parasite levels are believed to coincide with increased risk of 
maternal anaemia,14 resulting in an increased incidence of low birth weight 
deliveries.15 Maternal haematology is also highly indicative of foetal exposure 
levels, with cord microscopy proving the least conclusive.9,14,16,17 Given that 
the majority of malaria cases are seen in resource-poor environments with 
HEIEPA@ H=>KN=PKNU ?=L=>EHEPEAO ?KJłNI=PKNU @E=CJKOPE?IA=OQNAO OQ?D =O
these are simply not feasible. 
In most instances health workers must rely solely on symptoms and the 
probability of exposure to guide treatment. Any degree of parasitic infection 
during pregnancy increases the probability of both maternal and foetal 
death and should be controlled aggressively in order to prevent deleterious 
outcomes for both mother and unborn child.19
Treatment options
The management of malaria is multi-faceted and encompasses pre-and-
post-exposure control methods. Preventive techniques such as the use 
of insecticide-treated mosquito nets, residual insecticide spraying, and 
the administration of intermittent preventive treatment (IPT) have proved 
>AJAł?E=H EJ PDA łCDP =C=EJOP I=H=NE=1,4 Appropriate pharmacological 
management has been challenged during recent years with the emergence 
of multidrug-resistant (MDR) strains of P. falciparum.5 Resistance  to 
previously highly-effective antimalarials, exposes individuals to a greater 
threat of severe malaria and death.6
During the last three decades artemisinins have proved highly successful 
in their ability to clear patients of P. falciparum.19 0?EAJPEł? GJKSHA@CA
recognises the rapid parasitemia-clearing ability of artemisinins and the 
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highly successful post-treatment patient outcomes.20 However, most studies 
have investigated the use of artemisinins in non-pregnant patients, with 
limited research available pertaining to pregnant women. When animals are 
exposed to artemisinins, varying levels of embryotoxicity in early gestational 
LANEK@OD=RA>AAJE@AJPEłA@EJNK@AJPON=>>EPOBNKCO=J@IKJGAUO22-26
To date there have been no reported cases in which pregnant women 
receiving artemisinin treatment have experienced any complications or 
adverse outcomes that could not be attributed to the underlying pathology of 
the disease.27 Furthermore, there is a growing body of compelling evidence 
to attest to the comparative superiority of artemisinin compounds over 
alternative antimalarials in pregnancy . Studies have shown that artemisinin-
based combination therapies are well tolerated and exhibit fewer side-
effects, such as hypoglycaemia and tinnitus, commonly seen with quinine 
administration.28 Artemisinin use has resulted in equivalent to faster parasitic 
clearance and symptom resolution rates and is associated with fewer foetal 
adverse events.27-32 Furthermore, these compounds have shown non-
inferiority in regards to developmental milestones throughout gestation and 
PDAłNOPUA=NKBHEBA27-33 
Due to the vulnerability associated with malaria during pregnancy and the 
lack of substantial evidence supporting artemisinin use in early gestation, the 
WHO currently only endorses the administration of artemisinins in second- 
and third-trimester pregnancies. First-trimester artemisinin treatment is 
recommended only when there is a threat of severe malaria and where no 
other option is available.4 In these instances, treatment should be commenced 
without delay and with whatever pharmacological means are available.4 
Artemisinin antimalarial activity
For more than two thousand years the Chinese have relied on the healing 
properties of the perennial herb Artemisia annua in the treatment of chills 
and fevers.34 In 1971 Chinese scientists were able to isolate the artemisin 
or qinghaosu compound from the leaf of the A. annua plant.35 Synthetic 
derivatives such as artemether and artesunate have since been formulated 
and are seen to be more active than the parent molecule.36 Compared to 
OHKSAN=?PEJC=JPEI=H=NE=HO=NPAIEOEJEJOD=RA=RANU>NK=@OLA?Eł?EPU1DA
drug is capable of exterminating the malaria parasite throughout most stages 
of its life-cycle from the relatively inactive metabolic ring stage through to 
asexual reproduction and late schizont stages.37 
Artemisinins are known for their strong anti-plasmodial activity, eliminating 
parasitic biomass by 10-4KN>U=LLNKTEI=PAHUJEJAPUłRALAN?AJPSEPDEJ
hours of administration.34 Thus far, a dosage as low as 2 mg/kg has been 
noted to have dramatic parasitic clearance rates in humans.24 Unfortunately, 
when used mono-therapeutically in a short-course regimen, artemisinin 
compounds have displayed high recrudescence with failure rates of 
approximately eight percent in large cohort treatments. This is, however, 
PDKQCDP PK NAOQHP BNKI EJOQBł?EAJP PNA=PIAJP @QN=PEKJO =O KLLKOA@ PK
drug dosage levels or ineffectivity.34,37 Due to inadequate management 
practices, countries of the Greater Mekong sub-region now experience 
reduced susceptibility to  the artemisinin class,  highlighting the perpetual 
RQHJAN=>EHEPU KB =JPEI=H=NE=HO EJ PDA łCDP =C=EJOP I=H=NE=1 Regardless of 
this, to date artemisinins are still a more favourable alternative globally as 
compared to the widely-distributed quinine, which has a failure rate of up to 
thirty-three percent.27 
To prevent the development of resistance and recrudescence, it is advised 
that artemisinins be used jointly with a long-acting antimalarial in a regimen 
known as artemisinin-based combination therapy (ACT).3,34,37 Artemisinins 
have a short half-life of one hour, and when used in conjunction with a long-
=?PEJC=JPEI=H=NE=HOQ?D=OIAŃKMQEJA 1OODKSDECDANOQ??AOON=PAOSEPD
greater parasitic clearance and fewer episodes of recrudescence.34 
Mechanism of action
The pharmacokinetic properties of all artemisinins, regardless of varied 
synthesised or non-synthesised derivatives, are comparable to one another. 
Artemisinins require a one-electron transfer from a donor, such as ferrous iron 
(Fe2+), to activate an endoperoxide bridge resulting in either molecular alkalization 
or oxidation.38 It has therefore been elucidated that common effects would occur 
in all substances containing an endoperoxide bridge. Thus an artemisinin ‘class 
effect’ is likely during treatment, regardless of drug choice.39 
A clinical trial examining the developmental outcomes of rodent offspring 
post-artemisinin exposure has observed comparable results.38 It was 
found that equivalent exposure to four artemisinin compounds: artesunate, 
dihydroartemisinin (DHA), artemether and arteether, resulted in near-
AMQER=HAJPABBA?POEJPANIOKBAI>NUKHAPD=HEPU=J@PAN=PKCAJE?EPU?KJłNIEJC
the overall ‘class effect’ of embryotoxicity.38  Artemisinin-induced effects seen 
in animal trials range from anaemia and long bone curvature to gross skeletal 
malformation, cardiovascular and congenital abnormalities, to spontaneous 
abortion.39  It is important to note that, although the effects of artemisinin 
seem dire in these trials, the dosage used to induce such outcomes exceeds 
that which is required therapeutically in humans.
While research is slow to emerge regarding the mechanism and 
consequence of artemisinin toxicity during human pregnancy, growing 
knowledge surrounds the effects of exposure during the gestational period 
in animals.27 /A?AJP O?EAJPEł? EJRAOPEC=PEKJ EJRKHREJC =JEI=H OQ>FA?PO D=O
revealed that the primary cellular target of artesunate is the embryonic 
erythroblast.21 Artemisinin-induced primitive cell destruction is considered 
to be responsible for embryotoxicity in early trimester rodent pregnancies, 
with the incidence of cell destruction preceding any indication of foetal 
malformation or lethality.25  Primitive cells, abundant in Fe2+, are targeted as 
donors in order to perpetuate the mechanism of action of artemisinin.21,25 As 
a consequence, vital elements in cells are depleted, leading to cell necrosis. 
While erythrocytic destruction is not the primary target of the drug, it is an 
unfortunate side-effect. Loss of primitive erythroblasts during the narrow 
window of organogenesis is thought to induce foetal hypoxia causing a 
reduction in oxygen-enriched haeme, leading to cell growth retardation and 
destruction.25 
Bioavailability
The variability of embryotoxicity is dependent on dose, route, timing and 
@QN=PEKJ KB ATLKOQNA  ĺSEJ@KS KB OAJOEPEREPU D=O >AAJ E@AJPEłA@ EJ
rodents, whereby exposure to a single artesunate dose, between days ten 
and fourteen post-conception increased the prevalence of malformation 
and lethality.24  Although there is seemingly credible evidence to support 
PDA PKTE? N=IEł?=PEKJO KB =NPAIEOEJEJ =@IEJEOPN=PEKJ @QNEJC PDEO PEIA
frame, studies have suggested that repeated doses over a greater period 
are more consequential than single-dose exposure during this period of 
sensitivity.24,39,40 )ARAHO KB OAJOEPEREPU =NA =HOK OAAJ PK >A OLA?EAOOLA?Eł?
with primates displaying an increased resilience to toxicity compared to the 
highly-sensitive rodent.
To date, researchers have supported the general safety of oral artemisinin 
use during the second and third trimester, as few studies have reported 
evidence of malformation or abortion. Late gestational stage embryolethality 
D=O DKSARAN >AAJ E@AJPEłA@ EJ NK@AJPO EJPN=IQO?QH=NHU @KOA@SEPD DECD
levels of artesunate.23 These results are more likely attributable to the 
varied levels of systemic involvement between oral and intramuscular 
administration coupled with excessive exposure levels.22 Consequently, the 
route of administration appears to play a vital role in determining the level 
of toxicity experienced.41 Oral drug administration is noted to have weaker 
absorptive properties compared to the intravenous mode of delivery. In a 
clinical trial examining bio-availability, it was found that in order to induce 
LKOPEILH=JP=PEKJHEPPANHKOOEJLNACJ=JPNK@AJPO=JKN=H@KOAKB
mg/kg/day was required. A much lower dose of 1.5 mg/kg/day was required 
when administered intravenously.22 Results indicate that although the family 
of artemisinins collectively exhibit a class effect, the route of administration in 
conjunction with dose and exposure periods plays a vital role in determining 
maternal and foetal outcomes.
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Conclusion
Malaria has proven to be an enormous global burden, most severely affecting 
developing countries already suffering from economic and environmental 
hardships. The disease carries with it substantial morbidity and mortality, 
and the vulnerability of pregnancy enhances the risk of the mother developing 
severe malaria, greatly increasing the threat to the life of both the mother and 
unborn child.
Since inception in the marketplace, artemisinin derivatives have received 
great acclaim amongst scientists and in the international community, 
LNKREJCDECDHUABł?=?EKQO=C=EJOPPDA@=JCANKQOP. falciparum. Animal trials 
have enabled scientists to identify the synchronous effects of artemisinin 
dosing and embryonic toxicity during early gestation and organogenesis. 
Sensitivity levels vary between species, with rodents proving to be the most 
sensitive and primates more resistant, to experiencing artemisinin toxicity or 
lethality. Evidence suggests that artemisinin administered at extreme levels, 
far beyond what is required for parasitic clearance, have the potential to be 
lethal to the early developing embryo of animals. Whether or not similar levels 
of lethality would occur in humans is yet to be determined, although from 
the data currently available evaluating ACT versus alternative antimalarials 
including quinine, the results are indeed promising.
&JKN@ANPKBQHHUAHQ?E@=PAPDA>AJAłPO=J@NEOGOKB=NPAIEOEJEJATLKOQNAEJ
A=NHULNACJ=J?UIKNAOLA?Eł?=HHUP=NCAPA@NAOA=N?DEONAMQENA@1K@=PAPDA
risk of foetal complication from artemisinin exposure is non-inferior to that 
of current treatment methods. Future research focusing primarily on human 
and primate outcomes post-artemisinin exposure during early gestation is 
needed to guide policy and intervention programming.
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